吉西他滨联合多西他赛二线治疗进展期软组织肉瘤临床观察
摘要
目的:观察吉西他滨联合多西他赛(GT)方案治疗进展期软组织肉瘤(STS)患者的疗效和不良反应。方法:回顾收集进展期软组织肉瘤患者17例,采用GT方案治疗,观察GT方案治疗进展期软组织肉瘤的疗效和不良反应。结果:17例进展期软组织肉瘤患者共完成96个化疗周期,中位化疗周期数为6个(范围:1～9个)。3例(17.6%)患者为部分缓解,5例(29.4%)为疾病稳定,9例(53.0%)为疾病进展,疾病控制率达47.0%。中位无进展生存期为6.5个月,中位生存期为20.0个月。最常见的不良反应为骨髓抑制,其中3/4级不良反应主要为白细胞/中性粒细胞减少4例(23.5%)、血小板减少1例(5.9%)、贫血1例(5.9%)。无因不良反应导致退组或致死病例。结论:GT方案治疗进展期软组织肉瘤的疗效肯定且不良反应轻微可控,患者耐受性良好。
引文
[1] Clark MA, Fisher C, Judson I, et al. Soft-tissue sarcomas in adults[J]. N Engl J Med, 2005, 353(7):701-711.
[2] Hensley ML, Maki R, Venkatraman E,et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase Ⅱ trial [J].J Clin Oncol, 2002,20(12):2824-2831.
[3] Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase Ⅱ study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)[J]. Oncologist , 2012, 17(9):1213-1220.
[4] Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy[J]. J Clin Oncol, 2004, 22(8): 1480-1490.
[5] Skubitz KM, Skubitz AP. Differential gene expression in leiomyosarcoma[J].Cancer, 2003, 98(5):1029-1038.
[6] World Health Organization. Pathology and genetics of tumours of soft tissue and bone[M]. Lyon: IARC Press, 2002: 86-90.
[7] Santoro A,Tursz T,Mouridsen H,et al.Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas:a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group[J].J Clin Oncol,1995,13(7):1537-1545.
[8] Edmonson JH,Ryan LM,Blum RH,et al.Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin,doxorubicin, and cisplatin against advanced soft tissue sarcomas[J].J Clin Oncol,1993,1l(7):1269-1275.
[9] Oosten AW, Seynaeve C, Schmitz PI, et al. Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin[J]. Sarcoma ,2009,2009:348910-348916.
[10] Penel N, Italiano A, Isambert N, et al. Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin- containing chemotherapy[J]. Ann Oncol , 2010,21(6):1361-1365.
[11] Takana T, Niikura H, Ito K, et al. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan[J]. Int J Oncol, 2014,19(5):897-905.
[2] Hensley ML, Maki R, Venkatraman E,et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase Ⅱ trial [J].J Clin Oncol, 2002,20(12):2824-2831.
[3] Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase Ⅱ study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)[J]. Oncologist , 2012, 17(9):1213-1220.
[4] Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy[J]. J Clin Oncol, 2004, 22(8): 1480-1490.
[5] Skubitz KM, Skubitz AP. Differential gene expression in leiomyosarcoma[J].Cancer, 2003, 98(5):1029-1038.
[6] World Health Organization. Pathology and genetics of tumours of soft tissue and bone[M]. Lyon: IARC Press, 2002: 86-90.
[7] Santoro A,Tursz T,Mouridsen H,et al.Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas:a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group[J].J Clin Oncol,1995,13(7):1537-1545.
[8] Edmonson JH,Ryan LM,Blum RH,et al.Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin,doxorubicin, and cisplatin against advanced soft tissue sarcomas[J].J Clin Oncol,1993,1l(7):1269-1275.
[9] Oosten AW, Seynaeve C, Schmitz PI, et al. Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin[J]. Sarcoma ,2009,2009:348910-348916.
[10] Penel N, Italiano A, Isambert N, et al. Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin- containing chemotherapy[J]. Ann Oncol , 2010,21(6):1361-1365.
[11] Takana T, Niikura H, Ito K, et al. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan[J]. Int J Oncol, 2014,19(5):897-905.